ADLAI NORTYE LTD-ADR (ANL) Stock Price, Quote, News and Overview
NASDAQ:ANL - Nasdaq - US00704R1095 - ADR - Currency: USD
ANL Quote, Performance and Key Statistics
NASDAQ:ANL (5/7/2025, 8:00:00 PM)
1.8786
-0.15 (-7.23%)
The current stock price of ANL is 1.8786 USD. In the past month the price decreased by -6.54%. In the past year, price decreased by -85.6%.
ANL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.31 | 332.73B | ||
| AMGN | AMGEN INC | 13.29 | 148.31B | ||
| GILD | GILEAD SCIENCES INC | 12.78 | 123.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.78B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 60.56B | ||
| ARGX | ARGENX SE - ADR | 327.86 | 38.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.97B | ||
| ONC | BEIGENE LTD-ADR | N/A | 25.03B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.31B | ||
| NTRA | NATERA INC | N/A | 21.77B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.04B | ||
| BIIB | BIOGEN INC | 7.41 | 17.17B |
Related stock screener links
About ANL
Company Profile
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. The firm is involved in the research and development of pharmaceutical products. The company is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. The company is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. The company is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company’s subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.
Company Info
ADLAI NORTYE LTD-ADR
c/o PO Box 309, Ugland House
George Town KY
Employees: 127
Phone: 18482307430
ADLAI NORTYE LTD-ADR / ANL FAQ
What is the stock price of ADLAI NORTYE LTD-ADR today?
The current stock price of ANL is 1.8786 USD. The price decreased by -7.23% in the last trading session.
What is the ticker symbol for ADLAI NORTYE LTD-ADR stock?
The exchange symbol of ADLAI NORTYE LTD-ADR is ANL and it is listed on the Nasdaq exchange.
On which exchange is ANL stock listed?
ANL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ADLAI NORTYE LTD-ADR stock?
5 analysts have analysed ANL and the average price target is 9.18 USD. This implies a price increase of 388.66% is expected in the next year compared to the current price of 1.8786. Check the ADLAI NORTYE LTD-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ADLAI NORTYE LTD-ADR worth?
ADLAI NORTYE LTD-ADR (ANL) has a market capitalization of 69.32M USD. This makes ANL a Micro Cap stock.
How many employees does ADLAI NORTYE LTD-ADR have?
ADLAI NORTYE LTD-ADR (ANL) currently has 127 employees.
What are the support and resistance levels for ADLAI NORTYE LTD-ADR (ANL) stock?
ADLAI NORTYE LTD-ADR (ANL) has a resistance level at 2. Check the full technical report for a detailed analysis of ANL support and resistance levels.
Is ADLAI NORTYE LTD-ADR (ANL) expected to grow?
The Revenue of ADLAI NORTYE LTD-ADR (ANL) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ANL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ADLAI NORTYE LTD-ADR (ANL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANL, evaluating the profitability, health, valuation and growth aspects
- ADLAI NORTYE LTD-ADR (ANL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ADLAI NORTYE LTD-ADR (ANL) Sales and EPS estimates to see what analysts future expectations are.
- ADLAI NORTYE LTD-ADR (ANL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ADLAI NORTYE LTD-ADR (ANL) Insider and Institutional Ownership to learn about the owners and their transactions.
- ADLAI NORTYE LTD-ADR (ANL) Stock Chart to make your own analysis
- ADLAI NORTYE LTD-ADR (ANL) Latest news and press-releases to stay up to date.
Does ADLAI NORTYE LTD-ADR (ANL) stock pay dividends?
ANL does not pay a dividend.
What is the Price/Earnings (PE) ratio of ADLAI NORTYE LTD-ADR (ANL)?
ADLAI NORTYE LTD-ADR (ANL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.14).
What is the Short Interest ratio of ADLAI NORTYE LTD-ADR (ANL) stock?
The outstanding short interest for ADLAI NORTYE LTD-ADR (ANL) is 0.01% of its float. Check the ownership tab for more information on the ANL short interest.
ANL Technical Analysis
ANL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ANL. ANL may be in some trouble as it scores bad on both profitability and health.
ANL Financial Highlights
Over the last trailing twelve months ANL reported a non-GAAP Earnings per Share(EPS) of -5.14. The EPS decreased by -365.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -97.39% | ||
| ROE | -196.51% | ||
| Debt/Equity | 0.73 |
ANL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to ANL. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of 69.66% and a revenue growth -100% for ANL